PaulSWisselMD

PubMed

• 11 citations
  Encorafenib plus binimetinib in patients with-mutant non-small cell lung cancer: phase II PHAROS study design.
  Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Joh...> ;Future Oncology. 2022 Mar 1
• 7 citations
  A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer
  Jacob E. Shabason, Jerry Chen, Smith Apisarnthanarax, Nevena Damjanov, Bruce J. Giantonio, Arturo Loaiza-Bonilla, Peter J. O'Dwyer, Mark H. O'Hara, Kim A. Reiss, Ursin...> ;Cancer Chemotherapy and Pharmacology. 2018 Jan 23
• 33 citations
  A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular ...
  Tudor-Eliade Ciuleanu, Igor Bazin, D. Lungulescu, Lucian Miron, Igor Bondarenko, A. Deptala, M. Rodriguez-Torres, Bruce J. Giantonio, N. L. Fox, Paul Wissel, J.L. Egge...> ;Annals of Oncology. 2016 Apr 1
• 103 citations
  Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
  Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James M. Foran, Uwe Platzbecker, Norbert Vey, Roland B. Walter, Rebecca L. Olin, Azra Raza, Aristoteles Giagoun...> ;Cancer. 2016 Jun 15
• 60 citations
  Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carci...
  Kevin J. Harrington, Stéphane Temam, Hisham Mehanna, Anil K. D'Cruz, Minish Mahendra Jain, Ida D'Onofrio, Georgy M. Manikhas, Zsuzsanna Horvath, Yan Sun, Stefan Dietzs...> ;Journal of Clinical Oncology. 2015 Nov 2
• 15 citations
  Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
  B. Milojkovic Kerklaan, Martijn P. Lolkema, Lot A. Devriese, Emile E. Voest, A. Nol-Boekel, Marja Mergui-Roelvink, Marlies H.G. Langenberg, K. Mykulowycz, J Stoebenau,...> ;British Journal of Cancer. 2015 Sep 1
• 66 citations
  A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
  Davendra Sohal, K. Mykulowycz, Takeshi Uehara, Ursina R. Teitelbaum, Nevena Damjanov, Bruce J. Giantonio, Mary Carberry, Paul Wissel, Mona Jacobs-Small, Peter O'Dwyer,...> ;Annals of Oncology. 2013 Dec 1
• An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma:...
  Sun W, Sohal D, Mykulowycz K, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel PS, Jacobs-Small M, O'Dwyer PJ> ;J. Clin. Oncol.. 2012-02-01
• Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS muta...
  Borthakur G, Popplewell L, Kirschbaum MH, Foran JM, Kadia TM, Jabbour E, Boyiadzis M, Verma A, Walter RB, Wissel PS, Xu L, Bauman JW, Zhu JZ, Mazumdar J, Baccus M, Con...> ;J. Clin. Oncol.. 2011-05-20
• 53 citations
  Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving c...
  Steven M. Grunberg, Janusz Rolski, Janos Strausz, Zeba Aziz, Stephen J. Lane, Mark W. Russo, Paul Wissel, Mary E. Guckert, Oliver Wright, Jørn Herrstedt> ;The Lancet. Oncology. 2009 Jun 1
• 58 citations
  Adjuvant Therapy With the Monoclonal Antibody Edrecolomab Plus Fluorouracil-Based Therapy Does Not Improve Overall Survival of Patients With Stage III Colon Cancer
  Anthony L.A. Fields, Alan Keller, Lee S. Schwartzberg, Stephen A. Bernard, Carl Kardinal, Alan R. Cohen, Joe Schulz, Peter D. Eisenberg, John K. Forster, Paul Wissel> ;Journal of Clinical Oncology. 2009 Apr 20
• Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-Day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) i...
  Strausz J, Rolski J, Aziz Z, Guckert ME, Wright O, Bandekar RR, Thorn S, Wissel P, Herrstedt J> ;J. Clin. Oncol.. 2008-05-20
• Phase II trial of twice daily oral topotecan in combination with hyperfractionated radiotherapy for limited stage small cell lung carcinoma.
  Hodge CW, Legenne P, Wissel P, Schiller JH, Mehta MP> ;J. Clin. Oncol.. 2008-05-20
• 5 citations
  Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status
  Rogerio Lilenbaum, Rudolf M. Huber, Joseph Treat, Gregory A. Masters, Sabine Kaubitzsch, Stephen J. Lane, Paul Wissel> ;Clinical Lung Cancer. 2006 Sep 1
• Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
  Eckardt JR, Ramlau R, Gervais R, Shepherd F, O'Brien M, Ciuleanu T, Dharan B, Wissel P, Ross G> ;J. Clin. Oncol.. 2006-06-20
• 110 citations
  Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Ex...
  John R. Eckardt, Joachim von Pawel, Z. Papai, A. Tomova, Valentina Tzekova, T. Crofts, Sarah Brannon, Paul Wissel, Graham Ross> ;Journal of Clinical Oncology. 2006 May 1
• Comparable activity with oral topotecan/cisplatin (TC) and IV etoposide/cisplatin (PE) as treatment for chemotherapy-naïve patients (pts) with extensive disease small ...
  Eckardt JR, von Pawel J, Manikhas G, Papai Z, Tomova A, Tzekova V, Crofts T, Brannon S, Wissel P, Ross G> ;J. Clin. Oncol.. 2005-06-01
• 5 citations
  A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
  Della F. Makower, Joseph A. Sparano, Scott Wadler, Karen Fehn, Leon Landau, Paul Wissel, M. J. Versola, Sridhar Mani> ;Cancer Investigation. 2003 Mar 25
• 14 citations
  Androgen antagonists: Potential role in prostate cancer prevention
  Donald L. Trump, Joanne Waldstreicher, Geert J. C. M. Kolvenbag, Paul Wissel, Blake Lee Neubauer> ;Urology. 2001 Apr 1
• 23 citations
  Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers
  Howard E. Greenberg, Paul Wissel, Jeffrey S. Barrett, Aaron Barchowsky, Robert J. Gould, Daniel Farrell, Deborah Panebianco, Elizabeth Hand, Lisa Gillen, Michael R. Go...> ;Journal of Clinical Pharmacology. 2000 May 1
• 16 citations
  Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).
  C. Sessa, Jantien Wanders, M. Roelvink, P. Dombernowsky, D. Nielsen, R. Morant, P. Drings, P. Wissel, A.-R. Hanauske> ;Annals of Oncology. 2000 Feb 1
• 69 citations
  Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
  Alex Sparreboom, A. S. T. Planting, R. C. Jewell, M.E.L. van der Burg, A. van der Gaast, P. de Bruijn, Walter J. Loos, K. Nooter, L. H. Chandler, E. M. Paul, P. Wissel...> ;Anti-Cancer Drugs. 1999 Sep 1
• 16 citations
  Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion
  James P. Stevenson, D DeMaria, J. Sludden, Stan B. Kaye, L. Paz-Ares, Louise B. Grochow, A. McDonald, K. Selinger, P. Wissel, Peter J. O'Dwyer, Chris Twelves> ;Annals of Oncology. 1999 Mar 1
• 20 citations
  Evaluation of the feasibility and use of a prototype remote drug delivery capsule (RDDC) for non-invasive regional drug absorption studies in the GI tract of man and b...
  Alan F. Parr, Erik P. Sandefer, Paul Wissel, M. McCartney, Craig J. McClain, U. Y. Ryo, George A. Digenis> ;Pharmaceutical Research. 1999 Jan 1
• 18 citations
  A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
  L. Paz-Ares, R Kunka, D DeMaria, J. Cassidy, M Alden, P. Beranek, S. B. Kaye, D Littlefield, D Reilly, S. DePee, P. Wissel, Chris Twelves, Peter O'Dwyer> ;British Journal of Cancer. 1998 Nov 1
• Join now to see all